Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main ... ramped up its position in the US market with a string of supply agreements ...

Even the Hamburglar didn’t see this one coming.Excessive weight has been a persistent problem in America, where at least one ...

On a conference call, Lilly chief executive David Ricks said he was "not surprised" by the CVS Health development, given Zepbound is "gaining a lot of market share," but played down the ...